ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
April 15 2020 - 4:05PM
Business Wire
ACADIA to Host Conference Call and Webcast on
Thursday, May 7, 2020, at 4:30 p.m. Eastern Time
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it will report first quarter financial results on Thursday, May 7,
2020, after the close of the U.S. financial markets. ACADIA’s
management team will also host a conference call and webcast on
Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss
financial results and operations.
The conference call may be accessed by dialing 855-638-4820 for
participants in the United States or Canada and 443-877-4067 for
international callers (reference passcode 1974276). A
telephone replay of the conference call may be accessed through May
21, 2020 by dialing 855-859-2056 for callers in the United States
or Canada and 404-537-3406 for international callers (reference
passcode 1974276). The conference call also will be webcast live on
ACADIA’s website, www.acadia-pharm.com under the investors section
and will be archived there until June 4, 2020.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA has
developed and commercialized the first and only medicine approved
for the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. ACADIA also has ongoing clinical
development efforts in additional areas with significant unmet
need, including dementia-related psychosis, major depressive
disorder, the negative symptoms of schizophrenia, and Rett
syndrome. This press release and further information about ACADIA
can be found at: www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements regarding the
timing of future events. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to
various risks and uncertainties, including, among others,
unanticipated impacts of COVID-19 on ACADIA’s business, including
its commercial sales operations, current and planned clinical
trials and supply chain. For a discussion of these and other
factors, please refer to ACADIA’s annual report on Form 10-K for
the year ended December 31, 2019 as well as ACADIA’s subsequent
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200415005657/en/
Media Contact: ACADIA Pharmaceuticals Inc. Stephanie Fagan (858)
212-0534 media@acadia-pharm.com Investor Contact: ACADIA
Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771
ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024